Gut bacteria booster may help kidney cancer drugs work better
NCT ID NCT05122546
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether adding a probiotic called CBM588 to the standard combination of cabozantinib and nivolumab can improve treatment for advanced or metastatic kidney cancer. The probiotic is designed to restore helpful gut bacteria that may help the immune system fight cancer. The study involves 31 participants and focuses on changes in the gut microbiome and overall tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Clostridium butyricum CBM 588 probiotic strain
- What this could lead to
- If it works, this could show that adding a specific probiotic boosts the effectiveness of standard immunotherapy and targeted therapy for advanced kidney cancer.
- What could go wrong
- This is a very early, small phase 1 pilot study with only 31 participants. It primarily measures microbiome changes, not direct clinical benefit, so the results may not lead to a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill rewrite the genetic story of resistant kidney cancer?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Old drug, new hope: mercaptopurine tested against rare cancer syndrome
- New imaging agent aims to spot Hard-to-Find kidney cancer spread